Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.

about

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.

Item

http://www.wikidata.org/entity/Q47151381

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Feasibility, Safety, and Effic ...... cinoma: A Retrospective Study.

@en

Feasibility, Safety, and Effic ...... cinoma: A Retrospective Study.

@nl

type

Item

label

Feasibility, Safety, and Effic ...... cinoma: A Retrospective Study.

@en

Feasibility, Safety, and Effic ...... cinoma: A Retrospective Study.

@nl

prefLabel

Feasibility, Safety, and Effic ...... cinoma: A Retrospective Study.

@en

Feasibility, Safety, and Effic ...... cinoma: A Retrospective Study.

@nl

P1476

Feasibility, Safety, and Effic ...... rcinoma: A Retrospective Study

@en

P2093

Alessia Gattara

http://www.w3.org/2001/XMLSchema#string

Francesco Leonardi

http://www.w3.org/2001/XMLSchema#string

Maddalena Donini

http://www.w3.org/2001/XMLSchema#string

Rodolfo Passalacqua

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.

Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.

Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries

Molecular basis for sunitinib efficacy and future clinical development.

A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.

P304

585-596

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40268-017-0209-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sebastiano Buti

Melissa Bersanelli

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28895069

http://www.w3.org/2001/XMLSchema#string

P932

5694422

http://www.w3.org/2001/XMLSchema#string